Table 2. Characteristics of patients within included studies with established RA, stratified by data source.

Reference	Female (%)	Caucasian (%)	Age (years)	Disease duration (years)	RF+ (%)	DAS score (mean (SD))	HAQ score (mean (SD))	Physician type	DMARD use (%)	Combination DMARDs	Biologic DMARDs	Most common DMARD
Studies of Registries or Clinics
Yelin 2005	83	83	62	20	-	-	1.1 (-)	Rheum	90	-	32	MTX
Goycochea-Robles 2007	85	-	48	10	-	3.9 (1.3)	1.2 (0.8)	Rheum	93	41	6	MTX
Kahn 2007	78	83	54	10	-	-	-	Rheum	85	-	28	-
Yamanaka 2007	84	-	59	12	-	3.6 (-)	0.8 (-)	Rheum	90	-	3	MTX
Gonzalez-Alvaro 2008	72	-	61	13	75	4.1 (1.4)	1.2 (0.9)	Rheum	84	24	16	MTX
Sokka 2008(a)	71	-	54	6	70	-	0.6 (0.5, 0.7)*¥	Rheum	91	12	6	MTX
Teh 2008	84	0	53	5	66	4.3 (1.3)	-	Rheum	100	36	0	MTX
DeWitt 2009	78	87	65	24	-	-	1.4 (-)	Rheum	73	-	41	-
Soderlin 2010	74	-	63	14	-	-	0.75 (0.25–1.25)*	Rheum	87	-	20	MTX
Ziegler 2010	76	-	62	11	-	3.4 (1.3)	-	Rheum	85	23	16	MTX
Montag 2011	69	-	60	-		-	-	Rheum	92	26	15	MTX
Sung 2012	85	-	54	8	87	3.8 (1.4)	0.7 (0.7)	Rheum	98	67	6	MTX
Studies Using Administrative Data
Edwards 2005	71	-	58	9	-	-	-	Mixed	50	-	-	SSZ
Khanna 2007	77	95	47	-	-	-	-	Mixed	40	-	12	-
Schmajuk 2007	88	94	>65	-	-	-	-	Mixed	30	-	6	MTX
Grijalva 2008	78	74	57	-	-	-	-	Mixed	52	-	16	MTX
Schmajuk 2011	75	82	74	-	-	-	-	Mixed	63	-	-	-
Studies Using Population-Based Surveys
Westhoff 2009	-	-	-	9	41	2.9 (1.0)	-	Mixed	59	-	-	-
Della Rossa 2010	68	-	66	14	-	4.0 (-)	1.2 (-)	Mixed	73 §	5	-	MTX
Solomon 2012	76	82	>45	-	-		-	Mixed	47	-	15	-

- : not reported

DMARD: disease modifying drug

RF+: rheumatoid factor positive; DAS: disease activity score; HAQ: Health Activity Questionnaire;

Rheum: Rheumatologists; Mixed: Not restricted to rheumatologists; MTX: methotrexate; SSZ: sulfasalazine Numbers in italics are approximated from study data

^*mean(SD) not available; median (IQR) reported instead

^¥MHAQ reported instead of HAQ

^§personal communication ADR